Author:
Fujiwara Hiroyuki,Yokota Harushige,Monk Bradley,Treilleux Isabelle,Devouassoux-Shisheboran Mojgan,Davis Alison,Kim Jae-Weon,Mahner Sven,Stany Michael,Pignata Sandro,Ray-Coquard Isabelle,Fujiwara Keiichi
Abstract
Cervical adenocarcinoma is known to be less common than squamous cell carcinoma of the cervix comprising approximately 25% of all cervical carcinomas. Differences in associated human papillomavirus types, patterns of spread, and prognosis call for treatments that are not always like those for squamous cancers. In this review, we report a consensus developed by the Gynecologic Cancer InterGroup surrounding cervical adenocarcinoma for epidemiology, pathology, treatment, and unanswered questions. Prospective clinical trials are needed to help develop treatment guidelines.Key pointsDifferences between adenocarcinoma and squamous cell carcinoma, andIndividualization of the therapy
Subject
Obstetrics and Gynaecology,Oncology